Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA

Launched by FUDAN UNIVERSITY · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a specific type of metastatic colorectal cancer, which means the cancer has spread beyond the colon and rectum. Researchers are studying how a change in the RAS gene status, known as "NeoRAS Wild-type," can affect treatment decisions. This change can be identified through a simple blood test that checks for circulating tumor DNA (ctDNA). The goal is to find out how often this change happens and how it can help guide future treatments for patients with metastatic colorectal cancer.

To participate in this trial, patients need to have metastatic colorectal cancer that originally had a RAS mutation. They should also be in relatively good health, as indicated by an ECOG performance score of 0-1 (which means they are fully active or have some symptoms but are still able to carry out daily activities). Participants will be asked to provide blood samples and possibly tissue samples, and they will be monitored closely throughout the study. This trial is currently recruiting participants of all genders, aged 65 and older, and it offers a chance to contribute to important research that may lead to better treatment options for colorectal cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Metastatic colorectal cancer with tissue RAS mutation-type;
• • 2. ECOG (Eastern Cooperative Oncology Group) performance score is 0-1;
• • 3. Obtaining informed consent;
• • 4. Surgical specimens or punctured tissue specimens containing tumors can be obtained; 10ml of peripheral blood can be obtained
• Exclusion Criteria:
• • 1. The pathology was not confirmed by colonoscopy biopsy or biopsy of metastasis;
• • 2. Colorectal cancer patients with clinical stage I-III;Patients with RAS wild-type metastatic colorectal cancer confirmed by histological genetic testing;Lack of adequate organ functions, such as severe abnormalities in blood, liver and kidney function

Trial Officials